SHANGHAI – Upstart Beigene Co. Ltd. wowed observers last year when it landed two deals Merck Serono, a division of Merck KGaA, which licensed global rights to two of their preclinical oncology candidates for a combined value of close to $500 million. Out of the limelight, Beigene's momentum has not wavered. It has moved three oncology candidates into the clinic, the latest being Bruton tyrosine kinase (BTK) inhibitor, BGB-3111.
SHANGHAI – Upstart Beigene Co. Ltd. wowed observers last year when it landed two deals with Merck Serono, a division of Merck KGaA, which licensed global rights to two of their preclinical oncology candidates for a combined value of close to $500 million.
SHANGHAI – GC-Rise Pharmaceutical Co. Ltd. has received $15 million in series B financing from Orbimed Asia to pursue a strategy of in-licensing and commercializing products from the West to meet the growing health needs of women and children in China.
SHANGHAI – Eddingpharm Co. Ltd. began in 2001 by working with global companies in the spirit of partnership, by capitalizing on its knowledge of the China market for both its own and its partner's advantage. A second deal with nanobody developer Ablynx NV in less than a year shows it's continuing in this vein, making forays into the hairier terrain of biologics.
SHANGHAI – Zai Lab Inc., of Shanghai, has received $30 million in financing from a group of international venture capital investors, led by the well-respected Qiming Venture Partners LLC, headquartered in Hong Kong. The series A funding will support Zai's pursuit of its "virtual" business model, and the in-licensing and developing of innovative drugs for global markets as well as China.
SHANGHAI – Over the last few weeks, multinational pharmaceutical companies have received notification from the CFDA of an additional administrative hurdle that will likely delay drug approvals for innovative imported drugs by a year, or possibly longer.
SHANGHAI – Over the last few weeks, multinational pharmaceutical companies have received notification from the CFDA of an additional administrative hurdle that will likely delay drug approvals for innovative imported drugs by a year, or possibly longer.
SHANGHAI – Zai Lab Inc., of Shanghai, has received $30 million in financing from a group of international venture capital investors, led by the well-respected Qiming Venture Partners LLC, headquartered in Hong Kong. The series A funding will support Zai's pursuit of its "virtual" business model, and the in-licensing and developing of innovative drugs for global markets as well as China.
SHANGHAI – Hutchison China Meditech Ltd., also known as Chi-Med, said this month that phase III trials would be terminated for its lead candidate, HMPL-004, a botanical treatment for ulcerative colitis (UC).
SHANGHAI – Privately held Huya Bioscience International, of San Diego, has signed a strategic partnership with the Changzhou Center for Biotech Development (CZCBD) for the advancement of innovative drug and biomarker candidates.
